Hyperfine, Inc.

1.1600-0.07 (-5.69%)

Oct 29, 4:00:01 PM EDT · NasdaqGM · HYPR · USD

Upcoming Earnings

Report date

≈ Nov 12, 2025 (in 13 days)

Key Stats

Market Cap

109.58M

P/E (TTM)

Basic EPS (TTM)

-0.52

Dividend Yield

Recent Filings

8-K

Hyperfine Q3 revenue surges 27%

10/15/25Oct 15, 2025

Hyperfine reported preliminary Q3 2025 revenue of $3.4 million, up 27% sequentially, fueled by the next-generation Swoop system's rollout and Optive AI software upgrades. The company converted its entire U.S. hospital pipeline to these systems, placed them in critical care and emergency departments, and launched in office settings while rolling out AI software internationally. Cash burn dropped 27% to $5.9 million, leaving $21.6 million in cash. Momentum builds, yet figures remain unaudited and subject to change.

8-K

Q2 revenue surges 26%

8/13/25Aug 13, 2025

Hyperfine reported Q2 2025 revenue of $2.7 million, up 26% from Q1, fueled by 8 Swoop system sales versus 6 prior quarter, while gross margin climbed to 49.3%. FDA clearances for Optive AI software and next-gen Swoop scanner sparked commercial rollouts in hospitals and neurology offices, alongside promising ARIA-E detection data. Net loss narrowed to $9.2 million. Full-year revenue guidance holds at 10-20% above 2024, with cash burn cut 27% to $27-29 million midpoint. Momentum builds, yet clinical adoption risks linger.

10-Q

Q2 FY2025 results

8/13/25Aug 13, 2025

Hyperfine's Q2 revenue fell 25.8% y/y to $2.7M, with device sales down 28.4% from fewer units sold yet buoyed by higher pricing, while service revenue dipped 14.1%. Gross margin held steady at 50.7%, but operating loss narrowed 11.5% to $9.6M thanks to 23.8% lower R&D spend on reduced headcount. Diluted EPS improved to $(0.12) from $(0.14), confirmed against 78.1M weighted shares with anti-dilution from options and warrants. Cash burned $17.2M in operations, leaving $25.4M on hand after a $6M equity raise; free cash flow not disclosed in the 10-Q. FDA cleared the next-gen Swoop system in May 2025, promising sharper images and faster scans. Tariffs threaten supply chain costs.

8-K

Nasdaq compliance regained

8/6/25Aug 6, 2025

Hyperfine, Inc. regained Nasdaq compliance on August 6, 2025, after its Class A common stock met the $1.00 minimum bid price requirement, resolving a deficiency flagged in April. This closure averts delisting risks and stabilizes investor confidence. Compliance restored.

8-K

Board chair transition announced

5/23/25May 23, 2025

Hyperfine, Inc. announced on May 21, 2025, that R. Scott Huennekens resigned as Chairperson and Board member effective May 22, 2025, for personal reasons unrelated to any company disputes; the Board size shrank from six to five. Daniel J. Wolterman, an existing director, steps in as new Chairperson. Smooth transition preserves continuity. No disruptions disclosed.

About

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, New Zealand, and internationally. The company was founded in 2014 and is based in Guilford, Connecticut.

CEO

Ms. Maria Sainz

IPO

1/28/2021

Website

https://hyperfine.io

Employees

111

Sector

Healthcare

Industry

Medical Devices